The main targeted therapies for Acute Myeloid Leukemia (AML) include: FLT3 inhibitors For AML with FLT3 mutations, such as midostaurin, gilteritinib, etc. These target the FLT3 tyrosine kinase. Midostaurin[1] On April 28, 2017, the U.S. Food and Drug Administration approved midostaurin (RYDAPT, Novartis Pharmaceuticals Corp.) for the treatment of adult patients with newly diagnosed acute myeloid leukemia…
El 21 de marzo de 2023, LienTeh anunció una nueva estrategia de contenido destinada a proporcionar información y servicios de longevidad útiles, confiables y centrados en el usuario. Anteriormente, la Red LienTeh se creó originalmente para brindar apoyo durante la pandemia de COVID-19 al promover el equilibrio de atención médica…
On March 21, 2023, LienTeh announced a new content strategy aimed at providing useful, reliable and user-centric longevity information and services. Previously,The LienTeh Network was originally created to provide support during the COVID-19 pandemic by promoting cross-regional healthcare balance and improving access to healthcare resources. After that, the LienTeh network…
VIENTIANE, LAO PDR, March 6, 2023 -- The Lao Ministry of Health and the World Health Organization hosted an important GMP quality improvement meeting in Vientiane on March 1, attended by professionals from the local pharmaceutical industry. The purpose of this conference is to improve the quality of medicines in…
VIENTIANE, VIENTIANE, LAO PDR, March 3, 2023 -- BigBear pharmaceutical.LTD (BigBear pharma) announced that it has obtained the Good Manufacturing Practices (GMP) certificate issued by the Lao Food and Drug Regulatory Authority. The investor team of BigBear pharmaceutical went to Laos to investigate the investment environment in 2021, and formally…
VIENTIANE, LAOS, February 17, 2023 Laos Biospring.LTD and Singapore Zen science announced that the two parties have signed a joint venture agreement to establish a new joint venture company BioZen Health in Laos to engage in the manufacture and sale of high value-added medical beauty products and health food, and…
6 октября 2022 г., Вьентьян, Лаос — компания BioSpring («BioSpring Group.LTD», «BioSpring Group») выпускает таблетки BIODEUCRA (деукравацитиниб 6 мг) для лечения взрослых с бляшечным псориазом средней и тяжелой степени, которым показана системная терапия. или фототерапия. Деукравацитиниб, первый в своем классе пероральный селективный ингибитор аллостерической тирозинкиназы 2 (TYK2), является первым одобренным…
Ngày 06 tháng 10 năm 2022, Viêng Chăn, Lào - BioSpring ("BioSpring Group.LTD" "BioSpring Group") đang tung ra sản phẩm viên nén BIODEUCRA (Deucravacitinib 6mg) để điều trị cho người lớn bị bệnh vẩy nến thể mảng từ trung bình đến nặng, những người là ứng cử viên cho liệu…
First country in Latin America to sign a bilateral supply agreement thus expanding access to the monkeypox vaccine beyond the availability of vaccines through PAHO Additional supply agreement also signed with PAHO to expand availability for its member countries COPENHAGEN, Denmark, October 3, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced…
September 14, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") launches New Product Packaging for SaiLin's Global Market Customers. This product packaging upgrade is to fulfill the previous promise of BioSpring's acquisition of SaiLin, and will continue to provide follow-up support and services to Sailin's global customers. The batch will use…